XCath Timeline

Events

• 2026-10-08 - Regulatory - XCath’s Iris surgical robot enters FDA TAP programme - Enrollment follows Iris’s September 2, 2026 Breakthrough Device designation. A dedicated FDA advisor and review-team engagement will cover development decisions, with facilitated input from payers, providers and other stakeholders. Iris remains under… - source: wvva.marketminute.com
• 2026-04-23 - Deployment - XCath Iris completes first in-human telerobotic stroke procedure - Dr. Vitor Mendes Pereira operated from a control room in Santiago, Panama, about 200 kilometres from the patient at Panama Clinic in Panama City. The procedure was overseen locally by principal investigator Dr. Anastasio Ameijeiras Sibauste and used remote… - source: crescententerprises.com
• 2026-03-12 - Funding - XCath secures $30M Series C to advance neuro-endovascular surgical robotics - XCath announced a $30M Series C to support development and future commercialization of its endovascular surgical robot. The round was co-led by Crescent Enterprises and Dr. Fred Moll, chairman of XCath's board. The financing brought total capital raised… - source: businesswire.com
• 2025-11-12 - Deployment - XCath EVR robotic system performs first-in-human brain aneurysm procedures - XCath announced first-in-human use of its EVR robotic system to treat three patients with complex brain aneurysms at The Panama Clinic. The procedures marked only the second time a surgical robot had been used in an intracranial neurovascular intervention.… - source: massdevice.com
• 2022-01-01 - Funding - XCath $24M Series B (Crescent Enterprises 2022 report) - XCath raised additional funding, bringing total capital raised to $24M; Crescent Enterprises cited the round in its 2022 sustainability report. The financing supported advancement of XCath's neuro-endovascular robotic platforms toward regulatory clearances… - source: crescententerprises.com